These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 31664708)

  • 1. Dapagliflozin: A Review in Type 1 Diabetes.
    Paik J; Blair HA
    Drugs; 2019 Nov; 79(17):1877-1884. PubMed ID: 31664708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dapagliflozin: A Review in Type 2 Diabetes.
    Dhillon S
    Drugs; 2019 Jul; 79(10):1135-1146. PubMed ID: 31236801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium-glucose co-transporter inhibitors as adjunctive treatment to insulin in type 1 diabetes: A review of randomized controlled trials.
    Boeder S; Edelman SV
    Diabetes Obes Metab; 2019 Apr; 21 Suppl 2(Suppl 2):62-77. PubMed ID: 31081593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes.
    Watada H; Shiramoto M; Ueda S; Tang W; Asano M; Thorén F; Kim H; Yajima T; Boulton DW; Araki E
    Diabetes Obes Metab; 2019 Apr; 21(4):876-882. PubMed ID: 30499157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dapagliflozin for the treatment of type 1 diabetes mellitus.
    Pafili K; Maltezos E; Papanas N
    Expert Opin Investig Drugs; 2017 Jul; 26(7):873-881. PubMed ID: 28587531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.
    Henry RR; Rosenstock J; Edelman S; Mudaliar S; Chalamandaris AG; Kasichayanula S; Bogle A; Iqbal N; List J; Griffen SC
    Diabetes Care; 2015 Mar; 38(3):412-9. PubMed ID: 25271207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sotagliflozin: A Review in Type 1 Diabetes.
    Deeks ED
    Drugs; 2019 Dec; 79(18):1977-1987. PubMed ID: 31761990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefit/risk profile of dapagliflozin 5 mg in the DEPICT-1 and -2 trials in individuals with type 1 diabetes and body mass index ≥27 kg/m
    Mathieu C; Dandona P; Birkenfeld AL; Hansen TK; Iqbal N; Xu J; Repetto E; Scheerer MF; Thoren F; Phillip M
    Diabetes Obes Metab; 2020 Nov; 22(11):2151-2160. PubMed ID: 32691513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials.
    Groop PH; Dandona P; Phillip M; Gillard P; Edelman S; Jendle J; Xu J; Scheerer MF; Thoren F; Iqbal N; Repetto E; Mathieu C
    Lancet Diabetes Endocrinol; 2020 Oct; 8(10):845-854. PubMed ID: 32946821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes.
    Herring RA; Shojaee-Moradie F; Garesse R; Stevenage M; Jackson N; Fielding BA; Mendis A; Johnsen S; Umpleby AM; Davies M; Russell-Jones DL
    Diabetes Care; 2020 Sep; 43(9):2128-2136. PubMed ID: 32641376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dapagliflozin as an Adjunct Therapy to Insulin in Patients with Type 1 Diabetes Mellitus: Efficacy and Safety of this Combination.
    Jendle JH; Ampudia-Blasco FJ; Füchtenbusch M; Pozzilli P
    touchREV Endocrinol; 2021 Apr; 17(1):12-20. PubMed ID: 35118442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.
    Vivian EM
    Am J Health Syst Pharm; 2015 Mar; 72(5):361-72. PubMed ID: 25694411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
    Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
    Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomized Crossover Trial of Mixed Meal Tolerance Test Response in People with Type 1 Diabetes on Insulin Pump Therapy and YG1699 or Dapagliflozin.
    Lapuerta P; Urbina S; He J; Wittle A; Li C; Li T; Wang H; Hompesch M
    Clin Pharmacol Ther; 2024 Jun; 115(6):1383-1390. PubMed ID: 38456487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of dapagliflozin alone and in combination with insulin in a rat model of type 1 diabetes.
    Sayed N; Abdalla O; Kilany O; Dessouki A; Yoshida T; Sasaki K; Shimoda M
    J Vet Med Sci; 2020 Apr; 82(4):467-474. PubMed ID: 32161237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term (52-week) efficacy and safety of dapagliflozin as an adjunct to insulin therapy in Japanese patients with type 1 diabetes: Subgroup analysis of the DEPICT-2 study.
    Araki E; Mathieu C; Shiraiwa T; Maeda H; Ikeda H; Thoren F; Arya N; Asano M; Iqbal N
    Diabetes Obes Metab; 2021 Jul; 23(7):1496-1504. PubMed ID: 33620762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and pharmacodynamic properties of single- and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects.
    Yang L; Li H; Li H; Bui A; Chang M; Liu X; Kasichayanula S; Griffen SC; Lacreta FP; Boulton DW
    Clin Ther; 2013 Aug; 35(8):1211-1222.e2. PubMed ID: 23910664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary glucose excretion after dapagliflozin treatment: An exposure-response modelling comparison between Japanese and non-Japanese patients diagnosed with type 1 diabetes mellitus.
    Sokolov V; Yakovleva T; Ueda S; Parkinson J; Boulton DW; Penland RC; Tang W
    Diabetes Obes Metab; 2019 Apr; 21(4):829-836. PubMed ID: 30456904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of dapagliflozin as an adjunct therapy in patients with inadequately controlled type 1 diabetes mellitus.
    Van den Mooter L; Caerels S; Mathieu C
    Expert Opin Pharmacother; 2018 Apr; 19(6):617-622. PubMed ID: 29537892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.